GEMOPHARM LLC
The lead asset is the monoclonal antibody based on a proprietary therapeutic platform to target CD71 selectively in the tumor microenvironment. Gemopharm’s approach mitigates potential toxicities that may occur from solicitation of non-selective complement dependent cytotoxicity (CDC) activation or addition of a toxin payload. Gemopharm has generated in vivo proof-of-concept data demonstrating substantial efficacy and validating the mechanism of action of the lead candidate. The pilot toxicolo... gy has been completed without any signs of toxicity (no mortalities, clinical signs, or DLTs observed). Gemopharm envisages that its lead candidate can address a high unmet need for effective therapies for relapsed/refractory primary and secondary central nervous system (CNS) and intraocular lymphomas (IOL).
GEMOPHARM LLC
Industry:
Biotechnology Health Care Medical Medical Device Pharmaceutical
Founded:
2016-01-01
Address:
Moscow, Moscow City, Russian Federation
Country:
Russian Federation
Website Url:
http://www.gemopharm.ru
Total Employee:
1+
Status:
Active
Contact:
+79258753977
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx PHP
Similar Organizations
Cellective BioTherapy
Cellective BioTherapy develops novel cellular and monoclonal antibody-based platforms to treat cancer, autoimmunity, and immunodeficiency.
EntomoPharm
EntomoPharm, a biotechnology company, develops insect based screening models for predicting ADMET properties of chemical agents.
Current Employees Featured
Investors List
Primer Capital
Primer Capital investment in Venture Round - Gemopharm LLC
Official Site Inspections
http://www.gemopharm.ru
- Host name: 192.0.78.24
- IP address: 192.0.78.24
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
